RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Henan Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06817525, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 65 years; sex: women only

    Registered eligibility fields

  2. Thyroid stimulating hormone (TSH) ≤ upper limit of normal (ULN); If there are abnormalities, T3 and T4 levels should be examined. If T3 and T4 levels are normal, they can be selected

    Inclusion criterion 14

  3. Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy;

    Exclusion criterion 4

  4. ECOG score ≤ 1 point;

    Inclusion criterion 18

  5. Absolute value of neutrophil count ≥ 2.0 × 109/L

    Inclusion criterion 8

    Hemoglobin ≥ 100g/L

    Inclusion criterion 9

    Platelet count ≥ 100 × 109/L

    Inclusion criterion 10

    Total bilirubin<1.5 ULN (upper limit of normal)

    Inclusion criterion 11

    Creatinine<1.5 × ULN

    Inclusion criterion 12

    AST/ALT < 1.5×ULN;

    Inclusion criterion 13

    Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 ULN, while meeting international standards Normalization ratio (INR) ≤ 1.5 ULN (not receiving anticoagulant therapy);

    Inclusion criterion 15

  6. Women of childbearing age who tested negative for serum pregnancy test 14 days before randomization;

    Inclusion criterion 17

    Pregnant or lactating women;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06817525, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age: 18-65 years old;
  • Clinically and pathologically confirmed cT2- cT4d, or cT1c with axillary lymph node metastasis;
  • Three negative type and invasive breast cancer confirmed by histopathology;

Three negative breast cancer is defined as:

  • ER and PR negative (IHC nuclear staining<10%)
  • Her-2 negative (IHC 0, 1+without FISH, or IHC 2+without FISH amplification)
  • Clinically measurable lesions:

Measurable lesions displayed by ultrasound, mammography, or MR (optional) within one month prior to screening;

  • Organ and bone marrow function tests within 2 weeks before chemotherapy indicate no contraindications for chemotherapy:
  • Absolute value of neutrophil count ≥ 2.0 × 109/L
  • Hemoglobin ≥ 100g/L
  • Platelet count ≥ 100 × 109/L
  • Total bilirubin<1.5 ULN (upper limit of normal)
  • Creatinine<1.5 × ULN
  • AST/ALT < 1.5×ULN;
  • Thyroid stimulating hormone (TSH) ≤ upper limit of normal (ULN); If there are abnormalities, T3 and T4 levels should be examined. If T3 and T4 levels are normal, they can be selected
  • Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 ULN, while meeting international standards Normalization ratio (INR) ≤ 1.5 ULN (not receiving anticoagulant therapy);
  • Cardiac ultrasound EF value ≥ 55%;
  • Women of childbearing age who tested negative for serum pregnancy test 14 days before randomization;
  • ECOG score ≤ 1 point;
  • Voluntary signing of informed consent

Exclusion Criteria:

  • There is evidence of metastatic breast cancer (in order to exclude metastatic breast cancer, chest and abdomen CT and bone scanning should be performed at any time point before diagnosis and randomization; PET/CT scanning can be used as an alternative imaging inspection method);
  • Have Received chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. for this disease;
  • The patient has a second primary malignant tumor, in addition to: fully treated skin cancer;
  • Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy;
  • Diagnosed with immunodeficiency or autoimmune diseases;
  • Severe lung or heart disease;
  • Hepatitis B and C are in active phase;
  • History of organ transplantation or bone marrow transplantation;
  • Pregnant or lactating women;
  • Due to serious and uncontrollable medical conditions, researchers believe there are contraindications to chemotherapy;
  • Screening for clinically significant bleeding symptoms or significant bleeding tendencies within the previous month;
  • Screening for arteriovenous thrombosis events such as deep vein thrombosis and pulmonary embolism that occurred within the previous 3 months.

Quoted from ClinicalTrials.gov, NCT06817525, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06817525, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06817525